Disclosure of Technology. After Principal Investigator submits an invention disclosure covering any Technology to TSRI’s Office of Technology Development, TSRI shall disclose such Technology in writing to Sponsor (the “Technology Disclosure”). TSRI shall use reasonable efforts to provide a Technology Disclosure that contains sufficient detail to (i) enable both parties to determine whether or not the particular Technology is TSRI Technology or Joint Technology; and (ii) enable Sponsor to appreciate the significance of such Technology and to evaluate the advisability of exercising the option granted hereunder with respect to such Technology. All such Technology Disclosures shall be maintained in confidence by Sponsor.
Disclosure of Technology. Promptly following the execution of this Agreement, and periodically thereafter as such information becomes available to Licensor, Licensor shall provide to Licensee copies of all information and materials in tangible form related to the Technology that are reasonably necessary to or useful in the researching, making, using, selling, distributing, importing or exporting of Licensed Products. Without limiting the generality of the foregoing, if at any time Licensee elects to manufacture a Licensed Product, Licensor shall, upon notice from Licensee, transfer Licensed Know-How relating to manufacturing of the Licensed Product to Licensee, together with seed stock or other biological materials within the definition of Licensed Know-How.
Disclosure of Technology. At reasonable intervals during the three year period following the Effective Date, the parties shall meet to disclose technology developed by the parties which is included within the scope of the license each party granted to the other party under the terms of this Agreement. Any technology which is disclosed, including any material and information disclosed during the meetings, shall be subject to the provisions in this Agreement.
Disclosure of Technology. LICENSOR will supply NSC, as promptly as practicable after the Effective Date, and in any event within thirty (30) days of the Effective Date, with the Technology that will enable NSC to independently develop and manufacture the Licensed Products and obtain Regulatory Approvals. The parties agree to work in good faith to complete the provision of Technology to NSC within the time period set forth above. In addition, during such period, LICENSOR will grant NSC access, during normal business hours, to appropriate LICENSOR personnel for reasonable consultation related to the Licensed Technology in accordance with LICENSOR's regulations.
Disclosure of Technology. (a) GMI shall provide to Pfizer the GMI Know-How and a copy of filings, minutes and correspondence with a Regulatory Authority in its possession that may be necessary or useful to Pfizer to develop, manufacture, register, or market Licensed Products and efficiently practice the licenses granted under this Agreement within sixty (60) days of the Effective Date and thereafter (to the extent not previously disclosed and provided) no later than twenty (20) Business Days after such additional GMI Know-How becomes known or is acquired and a copy of filings, minutes and correspondence with a Regulatory Authority no later than twenty (20) Business Days after made, and after Completion of the Ongoing Clinical Trial, GMI shall transfer to Pfizer (i) within ten (10) Business Days after database lock for the Ongoing Clinical Trial all INDs and other filings, minutes and correspondence with a Regulatory Authority, and (ii) within a reasonable period of time after Completion of the Ongoing Clinical Trial, but in any event within ten (10) Business Days after receiving such information from the relevant service providers, any safety or pharmacovigilance databases, in each case, with respect to Licensed Product in the Territory. GMI shall bear its costs and expense for providing to Pfizer all of the information described above in this Section 2.3.
(b) In order to ensure the smooth transition of such GMI Know-How and development activities to Pfizer for the Compounds and Licensed Products that GMI has licensed to Pfizer pursuant to Section 2.1, each Party shall, at its own cost and expense (except as expressly set forth in the Schedule 2.3), carry out the activities to be performed by it as set forth in the transition plan attached hereto as Schedule 2.3 (the “Transition Plan”). If there is an inconsistency or disagreement between the Transition Plan and this Agreement, the terms of this Agreement shall prevail. Neither this Agreement nor the licenses granted hereunder shall be construed to confer any rights or licenses to Pfizer by implication, estoppel or otherwise as to any data, Know-How or Patent Rights other than GMI Patent Rights and GMI Know-How in accordance with the licenses granted under this Agreement.
(c) In addition to providing the information described in Section 2.3(a) and the transition services described in Section 2.3(b), at the request of Pfizer, GMI shall provide Pfizer with reasonable technical assistance with respect to understanding and implementing...
Disclosure of Technology. Except as otherwise set out in this Agreement, it is agreed that disclosure of data, information or technology by MIPI or EZN to the other Party shall not, except to the extent granted herein, constitute any grant, option or license under any patent, technology or other rights held by MIPI or EZN.
Disclosure of Technology. Enteris shall provide periodic written notice and disclosure to Cara of any and all Licensed Technology that is necessary or useful for the Manufacture, use or sale of the Product that is or comes under the Control of Enteris on or after the Effective Date and during the Term of the Agreement, except in the event that Cara exercises its Royalty Buyout, Enteris shall only provide notice to Cara under this Section 2.4 of any Licensed Technology that comes under the Control of Enteris after the Effective Date and on or prior to the date on which Enteris receives a payment from Cara in connection with the Royalty Buyout.
Disclosure of Technology. Upon the execution of this Agreement, and periodically thereafter upon request by PMC, VRI shall provide to PMC copies of all available information in tangible form within the Licensed Know-How or related to the Patent Rights.
Disclosure of Technology. Promptly after the Effective Date, and throughout the term of this Agreement, Vista shall make available to Urohealth, as reasonably requested by Urohealth, (i) copies of all patent applications within the Patent Rights, all correspondence and written materials related thereto, and all Related Technical Information; and (ii) all physical embodiments of the Patent Rights and Related Technical Information, including, without limitation, copies of all notebooks, drawings, diagrams, computer files, manuscripts, patent prosecution documents and other materials created or obtained in the course of developing the Patent Rights and/or Related Technical Information or related to their conception, experimentation, design, fabrication or use. Subject to Article 7 below and the licenses granted in Section 2.1 above, Urohealth may use and disclose such information and embodiments as it deems appropriate.
Disclosure of Technology. It is agreed that disclosure of data, information or technology by Nordion or Coulxxx, xx the other, during the Project shall not, except to the extent granted herein, constitute any grant, option or license under any patent, technology or other rights, held by Nordion or Coulxxx.
